Sustainability
Piramal Pharma’s GHG Commitment Validated and Approved by SBTi
Piramal Pharma Ltd.
PR-09-24-NI-04Sep 16, 2024
Female-Centric
Transforming Drug Development through a Female Perspective
Chia Chia Sun; William Freimuth, Ph.D., M.D.
Fab Biopharma
PAO-09-24-CL-03Sep 10, 2024
Monoclonal Antibodies
Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies
Coriolis Pharma
PR-05-24-NI-02Jun 18, 2024
Protein Degradation
PROTACS: Upgrading Small Molecule Inhibitors
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-24-NI-02Jun 11, 2024
CDMO - Small Biotech
Cis-Targeted Immunotherapies Need Large CDMO Expertise But Also Flexibility
Julie Trulson, Ph.D.
PAO-02-24-CL-07Feb 15, 2024
Tech Transfer
Transparent Communication Supports Tech Transfers Of Cis-targeted Immunotherapies
Julie Trulson, Ph.D.
PAO-02-24-CL-06Feb 15, 2024
Synthetic DNA
Is Synthetic Plasmid DNA One of the Solutions for Meeting Growing Demand for Next-Gen Therapies?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.
Pharma's Almanac
PAO-01-24-NI-04Feb 06, 2024
Retinal Disease
Pioneering Breakthroughs in Retinal Disease Treatment
David Alvaro, Ph.D.; David Zacks, M.D., Ph.D.; David Esposito
Pharma's Almanac
PAO-12-23-CL-01Dec 14, 2023
Supply Chain
Rethinking the Pharma/Biopharma Supply Chain to Maximize Resilience
Tim Tyson; Jesse McCool, Ph.D.; Russell Harris; Yongkwan Ma
TriRx Pharmaceutical Services
PTV-12-23-CL-02Dec 12, 2023
CDMO Selection
Why Fina Biosolutions Partnered With Scorpius BioManufacturing for cGMP Production of EcoCRM® (CRM197)
Scorpius BioManufacturing
PAO-11-23-CL-04Dec 08, 2023
CMC
The Biopharma Industry is Well Prepared for an Overhaul of the Lead-to-Clinic CMC Process for Antibodies
Jesse McCool, Ph.D.; David Schmidt, M.B.A., M.Sc.; Oren Beske, Ph.D.; Stephen Monks, Ph.D.
Wheeler Bio
PAO-07-23-CL-05Jul 26, 2023
Critical Cleaning
Aqueous Critical Cleaning for Pharma and Biopharma Applications (Companion to Aqueous Cleaning Handbook)
Michael Moussourakis
Alconox Inc.
PAO-04-23-CL-03Apr 20, 2023
UN Global Compact
CDMO Joins United Nations Global Compact
Vetter Pharma International GmbH
PR-M03-23-02Mar 08, 2023
Contamination Control Event
Ecolab and Pharma’s Almanac Present Contamination Control Event
David Alvaro, Ph.D.
Pharma's Almanac
PAO-11-022-CL-04Nov 15, 2022
Miniaturized Mass Spectrometry
Bringing Mass Spectrometry out of the Lab and to the Point of Need
Kevin J. Knopp, Ph.D.
PAO-09-022-CL-10Sep 27, 2022
Acquisition and Rebranding
Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding as AcuraBio
AcuraBio
PR-M09-22-01Sep 07, 2022
Plant-Inspired Drug Discovery
Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures
Andrea Small-Howard, Ph.D.
Gb Sciences, Inc.
PAO-08-022-CL-01Sep 06, 2022
Decontamination Solutions
A Guide on Comprehensive Decontamination Solutions for the Pharmaceutical Industry
Chris Berridge; Rolf Hansen, Ph.D.; Donald Singer
Ecolab
PAO-08-022-CL-08-254Aug 24, 2022
New Project Funding
NIIMBL Announces $15.8M to Fund 14 New Biopharmaceutical Manufacturing Projects
NIIMBL
PR-M08-22-02-279Aug 09, 2022
Contamination Control
Contamination Control Strategies for the Manufacture of Conventional and Next-Generation Biologics
Chris Berridge; Rolf Hansen, Ph.D.; Donald Singer
Ecolab
PAO-07-022-CL-07Jul 20, 2022